Abstract
Galectin-3 influences neoangiogenesis, tumor cell adhesion, and tumor-immune-escape mechanisms. Hence, the expression of galectin-3 in pancreatic ductal adenocarcinoma (PDAC) was evaluated. Galectin-3 expression in PDAC cell lines was proven by the presence of intracellular protein and by release into the supernatant. Furthermore, galectin-3 was found in the majority of human tissue samples. Serum concentrations of galectin-3 in PDAC patients did not differ significantly from healthy donors and did not correlate with established tumor markers. In conclusion, galectin-3 is expressed in PDAC tissues suggesting a role in tumor development; however, no relationship between expression and clinical findings could be established.
MeSH terms
-
Adenocarcinoma / genetics
-
Adenocarcinoma / metabolism*
-
Adenocarcinoma / mortality
-
Adult
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / metabolism*
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / metabolism*
-
Carcinoma, Pancreatic Ductal / mortality
-
Case-Control Studies
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Follow-Up Studies
-
Galectin 3 / genetics
-
Galectin 3 / metabolism*
-
Humans
-
Immunoenzyme Techniques
-
Male
-
Middle Aged
-
Neoplasm Invasiveness
-
Neoplasm Staging
-
Pancreas / metabolism*
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / metabolism*
-
Pancreatic Neoplasms / mortality
-
Prognosis
-
RNA, Messenger / genetics
-
Real-Time Polymerase Chain Reaction
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Rate
-
Tumor Cells, Cultured
Substances
-
Biomarkers, Tumor
-
Galectin 3
-
RNA, Messenger